Pregled bibliografske jedinice broj: 290443
CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia
CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia // Abstracts of the 10th Congress of the European Federation of Neurological Societies
Glasgow, Ujedinjeno Kraljevstvo, 2006. (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 290443 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
CSF levels of total tau protein, phosphorylated tau epitopes 181, 199 and 231 as markers for early-onset Alzheimer's dementia
Autori
Boban, Marina ; Grbić, Kristina ; Hof, Patrick ; Hamann, Christine ; Ackl, Nibal ; Bader, Benedikt ; Danek, Adrian ; Šimić, Goran
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Abstracts of the 10th Congress of the European Federation of Neurological Societies
/ - , 2006
Skup
10th Congress of European Federation of Neurological Societies
Mjesto i datum
Glasgow, Ujedinjeno Kraljevstvo, 02.09.2006. - 05.09.2006
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Alzheimer's disease; tau protein; cerebrospinal fluid; early-diagnosis; biological markers
Sažetak
Abnormal hyperphosphorylation of the microtubule-associated protein tau and its incorporation into neurofibrillary tangles are major hallmarks of the pathogenesis of Alzheimer's disease (AD). The cerebrospinal fluid (CSF) levels of phosphorylated tau proteins reflect the phosphorylation state of tau in the brain. Using monoclonal antibodies, different tau phosphoepitopes can be sensitively detected in CSF. To determine the diagnostic value of CSF total tau protein (t-tau), tau protein phosphorylated at threonine 181, 199 and 231 (p-tau-181, p-tau-199, p-tau-231) in early onset Alzheimer disease (AD) versus other primary causes of dementia (such as frontotemporal dementia (FTD)). Patients with clinical diagnosis of MCI (mild cognitive impairment), probable and possible AD, as well as FTD and nondemented controls were included in the study. CSF levels of t-tau, p-tau-181, p-tau-199, p-tau-231 were measured using commercially available ELISA kits (Invitrogen-Biosource, Camarillo, CA, USA). Mean CSF t-tau and CSF p-tau-181 levels were significantly elevated in AD patients compared to FTD patients and control subjects. Additionally, in differentiation between AD and FTD, CSF p-tau 181 showed best sensitivity and specificity. Our preliminary results in a rather small group of patients with AD and FTD confirmed earlier findings that p-tau-181 may be an useful, promising biological marker for distinguishing primary causes of dementia (e.g. AD from FTD).
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti, Psihologija
Napomena
European Journal of Neurology (1351-5101) 13 (2006) (S2) 196-197
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE